Covaxin showed 81% interim efficacy: Bharat Biotech on Phase 3 results

Covaxin demonstrates significant immunogenicity against the rapidly emerging variants, says Bharat Biotech CMD

Covaxin
Premium

The interim analysis was based on 43 recorded cases of Covid-19 in the trial of 25,800 participants (Photo: Bloomberg)

BS Web TeamAgencies New Delhi
Bharat Biotech's homegrown Covid-19 vaccineç Covaxin, has shown an interim vaccine efficacy of 81% in late-stage clinical trials, the Hyderabad-based company said on Wednesday. That’s better than Bharat Biotech’s guidance last year of around 60% and India’s benchmark of 50% for vaccines targeting the novel coronavirus.

The trials involved 25,800 participants and was conducted in partnership with Indian Council of Medical Research (ICMR), the Indian government's medical research body. This was the largest ever trial conducted in India. 

"The Phase 3 study enrolled 25,800 participants between 18-98 years of age, including 2,433 over the age of 60 and 4,500

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Mar 03 2021 | 5:11 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com